Showing 1 - 8 results of 8 for search 'Akihiko Asahina', query time: 0.04s
Refine Results
-
1
-
2
-
3
A case of concurrent exacerbation of manifestations and asthma after the initiation of nemolizumab treatment for atopic dermatitis by Michie Katsuta, MD, Ayaka Osawa, MD, Yozo Ishiuji, MD, Satomi Fujii, MD, Masahiro Kanbe, Akihiko Asahina, MD, Yoshimasa Nobeyama, MD
Published 2025-07-01Get full text
Article -
4
Relationship between the Degrees of Itch and Serum Lipocalin-2 Levels in Patients with Psoriasis by Norie Aizawa, Yozo Ishiuji, Mitsutoshi Tominaga, Sanae Sakata, Nobuaki Takahashi, Koichi Yanaba, Yoshinori Umezawa, Akihiko Asahina, Utako Kimura, Yasushi Suga, Kenji Takamori, Hidemi Nakagawa
Published 2019-01-01Get full text
Article -
5
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies by Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Laure Gossec, Iain B. McInnes, Christopher T. Ritchlin, Robert B. M. Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates
Published 2024-08-01Get full text
Article -
6
Correction: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies by Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Laure Gossec, Iain B. McInnes, Christopher T. Ritchlin, Robert B. M. Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates
Published 2025-05-01Get full text
Article -
7
Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies by Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Laure Gossec, Iain B. McInnes, Christopher T. Ritchlin, Robert B. M. Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates
Published 2025-05-01Get full text
Article -
8
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III... by Robert Landewé, Joseph F Merola, Laure Gossec, Frank Behrens, Ana-Maria Orbai, Philip J Mease, Iain B McInnes, Yoshiya Tanaka, Dafna D Gladman, Laura C Coates, Alice B Gottlieb, Vishvesh Shende, Jason Coarse, Christopher T Ritchlin, Richard B Warren, Akihiko Asahina, Barbara Ink, Rajan Bajracharya
Published 2024-02-01Get full text
Article